NYSE: CLX
Clorox
Consumer Staples · Specialty Cleaning, Polishing and Sanitation Preparations
52-week range
Stock price
Market cap
At each fiscal year end, then the latest quarter end: closing price × shares outstanding.Figures shown are for the trailing 12 months to Mar 31, 2026. Hover or tap a column for another year.$12.5B
Show tableHide table
| Period | Market cap |
|---|---|
| FY2016, ended Jun 30, 2016 | $17.9B |
| FY2017, ended Jun 30, 2017 | $17.2B |
| FY2018, ended Jun 30, 2018 | $17.3B |
| FY2019, ended Jun 30, 2019 | $19.3B |
| FY2020, ended Jun 30, 2020 | $27.7B |
| FY2021, ended Jun 30, 2021 | $22.1B |
| FY2022, ended Jun 30, 2022 | $17.4B |
| FY2023, ended Jun 30, 2023 | $19.7B |
| FY2024, ended Jun 30, 2024 | $16.9B |
| FY2025, ended Jun 30, 2025 | $14.7B |
| Trailing 12 months to Mar 31, 2026 (through Q3 FY2026) | $12.5B |
Revenue
By fiscal year, then the trailing 12 months.Figures shown are for the trailing 12 months to Mar 31, 2026. Hover or tap a column for another year.$6.76B
Show tableHide table
| Period | Revenue |
|---|---|
| FY2016, ended Jun 30, 2016 | $5.76B |
| FY2017, ended Jun 30, 2017 | $5.97B |
| FY2018, ended Jun 30, 2018 | $6.12B |
| FY2019, ended Jun 30, 2019 | $6.21B |
| FY2020, ended Jun 30, 2020 | $6.72B |
| FY2021, ended Jun 30, 2021 | $7.34B |
| FY2022, ended Jun 30, 2022 | $7.11B |
| FY2023, ended Jun 30, 2023 | $7.39B |
| FY2024, ended Jun 30, 2024 | $7.09B |
| FY2025, ended Jun 30, 2025 | $7.10B |
| Trailing 12 months to Mar 31, 2026 (through Q3 FY2026) | $6.76B |
Net income and free cash flow
By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.Figures shown are for the trailing 12 months to Mar 31, 2026. Hover or tap a column for another year.Show tableHide table
| Period | Net income | Free cash flow |
|---|---|---|
| FY2016, ended Jun 30, 2016 | $648M | $606M |
| FY2017, ended Jun 30, 2017 | $701M | $634M |
| FY2018, ended Jun 30, 2018 | $823M | $782M |
| FY2019, ended Jun 30, 2019 | $820M | $786M |
| FY2020, ended Jun 30, 2020 | $939M | $1.29B |
| FY2021, ended Jun 30, 2021 | $710M | $945M |
| FY2022, ended Jun 30, 2022 | $462M | $535M |
| FY2023, ended Jun 30, 2023 | $149M | $930M |
| FY2024, ended Jun 30, 2024 | $280M | $483M |
| FY2025, ended Jun 30, 2025 | $810M | $761M |
| Trailing 12 months to Mar 31, 2026 (through Q3 FY2026) | $756M | $380M |
Cash and cash equivalents
At each fiscal year end, then the latest quarter end.Figures shown are for the trailing 12 months to Mar 31, 2026. Hover or tap a column for another year.$1.19B
Show tableHide table
| Period | Cash and cash equivalents |
|---|---|
| FY2016, ended Jun 30, 2016 | $401M |
| FY2017, ended Jun 30, 2017 | $418M |
| FY2018, ended Jun 30, 2018 | $131M |
| FY2019, ended Jun 30, 2019 | $111M |
| FY2020, ended Jun 30, 2020 | $871M |
| FY2021, ended Jun 30, 2021 | $319M |
| FY2022, ended Jun 30, 2022 | $183M |
| FY2023, ended Jun 30, 2023 | $367M |
| FY2024, ended Jun 30, 2024 | $202M |
| FY2025, ended Jun 30, 2025 | $167M |
| Trailing 12 months to Mar 31, 2026 (through Q3 FY2026) | $1.19B |
Total debt
At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.Figures shown are for the trailing 12 months to Mar 31, 2026. Hover or tap a column for another year.$4.08B
Show tableHide table
| Period | Total debt |
|---|---|
| FY2016, ended Jun 30, 2016 | $2.31B |
| FY2017, ended Jun 30, 2017 | $2.19B |
| FY2018, ended Jun 30, 2018 | $2.48B |
| FY2019, ended Jun 30, 2019 | $2.68B |
| FY2020, ended Jun 30, 2020 | $2.78B |
| FY2021, ended Jun 30, 2021 | $2.78B |
| FY2022, ended Jun 30, 2022 | $2.71B |
| FY2023, ended Jun 30, 2023 | $2.53B |
| FY2024, ended Jun 30, 2024 | $2.48B |
| FY2025, ended Jun 30, 2025 | $2.49B |
| Trailing 12 months to Mar 31, 2026 (through Q3 FY2026) | $4.08B |
Shares outstanding
At each fiscal year end, then the latest quarter end, adjusted for splits. Down 6.6% since 2016.Figures shown are for the trailing 12 months to Mar 31, 2026. Hover or tap a column for another year.121M
Show tableHide table
| Period | Shares outstanding |
|---|---|
| FY2016, ended Jun 30, 2016 | 129M |
| FY2017, ended Jun 30, 2017 | 129M |
| FY2018, ended Jun 30, 2018 | 128M |
| FY2019, ended Jun 30, 2019 | 126M |
| FY2020, ended Jun 30, 2020 | 126M |
| FY2021, ended Jun 30, 2021 | 123M |
| FY2022, ended Jun 30, 2022 | 123M |
| FY2023, ended Jun 30, 2023 | 124M |
| FY2024, ended Jun 30, 2024 | 124M |
| FY2025, ended Jun 30, 2025 | 122M |
| Trailing 12 months to Mar 31, 2026 (through Q3 FY2026) | 121M |
Buybacks and new shares
By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.Figures shown are for the trailing 12 months to Mar 31, 2026. Hover or tap a column for another year.Net: $265M more bought back than issued
Show tableHide table
| Period | Bought back | Paid to employees |
|---|---|---|
| FY2016, ended Jun 30, 2016 | $254M | $45.0M |
| FY2017, ended Jun 30, 2017 | $183M | $51.0M |
| FY2018, ended Jun 30, 2018 | $271M | $53.0M |
| FY2019, ended Jun 30, 2019 | $661M | $43.0M |
| FY2020, ended Jun 30, 2020 | $248M | $50.0M |
| FY2021, ended Jun 30, 2021 | $905M | $50.0M |
| FY2022, ended Jun 30, 2022 | $25.0M | $52.0M |
| FY2023, ended Jun 30, 2023 | $0 | $73.0M |
| FY2024, ended Jun 30, 2024 | $0 | $74.0M |
| FY2025, ended Jun 30, 2025 | $332M | $81.0M |
| Trailing 12 months to Mar 31, 2026 (through Q3 FY2026) | $331M | $66.0M |
Revenue (TTM)
$6.76B
−3.7% YoY
Net income (TTM)
$756M
+8.9% YoY
Cash
$1.19B
+425% YoY
Total debt
$4.08B
+60.7% YoY
Valuation
At current price- Market Cap
- $10.6B
- P/E
- 14.1×
- Forward P/E
- —. Needs analyst estimates; not available from the current data provider
- Price / Sales
- 1.6×
- Price / Book
- n/m. Market cap / shareholders' equity
- EV / EBITDA
- 10.3×
Growth
Trailing 12 months- Revenue (TTM)
- $6.76B
- Revenue Growth YoY
- −3.7%
- Revenue CAGR 3Y
- −0.0%
- Revenue CAGR 5Y
- 1.1%
- EPS Growth YoY
- 10.4%
- Net Income Growth YoY
- 8.9%
Profitability
Trailing 12 months- Gross Margin
- 43.8%
- Operating Margin
- —
- Net Margin
- 11.2%
- FCF Margin
- 5.6%
- Return on Equity
- n/m. Net income (TTM) / average equity
Earnings
Trailing 12 months- Net Income
- $756M
- EPS (diluted)
- $6.15
- EBITDA
- $1.31B
- Operating Income
- —
Balance Sheet
As of Mar 31, 2026- Cash and cash equivalents
- $1.19B
- Total Debt
- $4.08B
- Net Debt
- $2.89B
- Total Assets
- $6.44B
- Total Liabilities
- $6.34B
- Shareholders' Equity
- −$67.0M
Cash Flow
Trailing 12 months- Operating Cash Flow
- $576M
- Capital Expenditure
- $196M
- Free Cash Flow
- $380M
Dividends and risk
Last 12 months- Dividend Yield
- 5.7%
- Dividend / Share
- $4.98
- Beta (5Y)
- 0.58
Every ratio is calculated from the company’s reported figures.
Note
Revenue is roughly flat year over year at $6.76B.
Note
Net margin of 11.2% over the last 12 months.
Note
Net debt of $2.89B is 2.2× EBITDA.
Note
Free cash flow of $380M, 5.6% of revenue.
Written by fixed rules from the reported figures, not by a person or an AI.
Latest report
Pro10-K for the fiscal year ended Jun 30, 2013 · filed Aug 23, 2013
The score and findings for the newest report are part of CoreStock Pro, coming soon. Every earlier report is free.
Score of each annual report
0 to 100 · 60 means nothing notable · tap a column for its details
2012 · 10-K68Mildly positive
10-K for the fiscal year ended Jun 30, 2012
Filed Aug 24, 2012 · Read the filing on EDGAR
- Net sales rose about 4.5% to $5.47 billion, and pre-tax earnings rose about 40% to $791 million, per the segment table.
- The profit jump mostly reflects last year's $258 million Burt's Bees goodwill charge; excluding it, pre-tax earnings would have slipped from about $821 million.
- Clorox bought HealthLink, Aplicare and Soy Vay, and launched a record level of new products.
- Clorox expects further cost increases in fiscal 2013 and plans price rises that could slow sales; $850 million of notes also mature that year.
Business momentum
Strong improvement
“In fiscal year 2012, the Company celebrated numerous successes.”
Outlook
Cautious
“The Company anticipates taking some price increases across its global portfolio in fiscal year 2013, which may slow sales growth or create volume declines in the short term”
Financial stress
Low
“the Company currently generates significant cash flows from ongoing operations and has access to global credit markets through its financing activities and existing credit facilities to meet its current needs”
Tone against the previous report
About the same
Red flags
None found in this report.
Positives
Record level of new products alongside small acquisitions
“The Company expanded its product portfolio through innovation and bolt-on acquisitions, delivering a record level of new products”
Expansion into faster-growing healthcare categories
“The Company also acquired HealthLink and Aplicare, Inc., leading providers of infection control products that increase the Company’s exposure to faster-growing categories”
Concentrated bleach should improve performance and lower costs
“Clorox® Concentrated Regular-Bleach, which enables better product performance and a reduction in the Company’s costs and environmental footprint”
Concerns
Raw material and other costs are expected to keep rising
“The Company anticipates continued commodity and other price increases in fiscal year 2013”
Reported profit growth was helped by last year's large goodwill charge
“Fiscal year 2011 earnings (losses) from continuing operations before income taxes for the Lifestyle and International reportable segments included a noncash goodwill impairment charge of $164 and $94, respectively, for the Burt’s Bees business.”
Heavy reliance on Walmart for sales
“Net sales to the Company’s largest customer, Walmart Stores, Inc. and its affiliates, were 26%, 27% and 27% for the fiscal years ended 2012, 2011 and 2010”
New risks since the previous report
Venezuela's high inflation and currency devaluation will keep hurting results
“the potential for further devaluation of the local currency exchange rate will continue to negatively affect the Company’s revenue, operating profit and net income in fiscal year 2013 and beyond”
Another activist takeover proposal could be costly and disruptive
“During fiscal years 2012 and 2011, the Company was the target of an unsolicited takeover proposal from a shareholder activist, which resulted in significant costs to the Company.”
Large debt repayment due within the coming year
“As of June 30, 2012, the Company had $2.7 billion of debt, including $850 million of senior unsecured notes that mature in fiscal year 2013.”
Newly acquired healthcare businesses bring extra regulation
“These risks may be increased by the Company’s recent acquisitions of HealthLink and Aplicare, Inc., which manufacture products subject to additional regulations.”
Biggest risks named
- Rising raw material, energy and transportation costs
- Economic and currency instability, especially in Venezuela and Argentina
- Dependence on Walmart and other large customers
- Intense competition from larger rivals and store brands
- Substantial debt, including $850 million maturing in fiscal 2013
Artificial intelligence in this business: Not mentioned
How the score adds up
| Starting point | 60 | |
| Business momentum | +12 | |
| Outlook | −2 | |
| Tone against the previous report | 0 | |
| Financial stress | 0 | |
| Red flags | 0 | |
| New risks | −2 | |
| Score | 68 | |
Written by AI (Claude Opus 5.5) from the report’s text. 13 of 13 quotes were found word for word in the filing; the rest are left out. Not investment advice.
All scored reports
| Period | Report | Filed | Score | Momentum | Red flags |
|---|---|---|---|---|---|
| 10-K | Aug 23, 2013 | Pro | |||
| 10-K | Aug 24, 2012 | 68 | Strong improvement | None | |
| 10-K | Aug 26, 2010 | 66 | Improving | None | |
| 10-K | Aug 25, 2009 | 64 | Improving | None | |
| 10-K | Aug 19, 2008 | 62 | Stable | None | |
| 10-K | Aug 25, 2006 | 60 | Stable | 1 minor | |
| 10-K | Aug 27, 2004 | 61 | Stable | 1 minor | |
| 10-K | Sep 19, 2003 | 58 | Stable | 1 minor | |
| 10-K | Sep 26, 2000 | 61 | Stable | None | |
| 10-K | Sep 28, 1999 | 60 | Stable | None |
How these scores work
An AI model reads the management discussion, risk factors and legal sections of each report and records what they say, quoting the filing word for word. Fixed rules then turn those findings into a score from 0 to 100, where 60 means nothing notable either way. A score describes the report, not whether the stock is a good investment, and the AI may know how things turned out later, which can colour older scores. Read the methodology
From the 10-Q for Q3 FY2026 (period ended Mar 31, 2026), filed Apr 30, 2026. View filings on SEC EDGAR